Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for inhibiting methicillin-resistant staphylococcus aureus biofilm

A methicillin- and staphylococcus-resistant technology is applied in the field of compositions for inhibiting methicillin-resistant Staphylococcus aureus biofilms, which can solve the problems of difficult treatment, persistent infection and easy recurrence, and achieve the effect of enhanced synergy.

Inactive Publication Date: 2018-07-13
GUANGXI MEDICAL UNIVERSITY
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, clinically, it is relatively difficult to treat medical material-related infections caused by MRSA biofilms, and the infections are persistent and easy to recur. Central venous catheter, artificial heart

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for inhibiting methicillin-resistant staphylococcus aureus biofilm
  • Composition for inhibiting methicillin-resistant staphylococcus aureus biofilm
  • Composition for inhibiting methicillin-resistant staphylococcus aureus biofilm

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Example 1 Inhibition of methicillin-resistant Staphylococcus aureus biofilm composition test

[0052] Materials and Reagents:

[0053] 1. Carrier:

[0054] Medical silicone sheet (1cm 2 )

[0055] 2. Experimental strains:

[0056] Methicillin-resistant Staphylococcus aureus (MRSA) standard strain: ATCC29213 (provided by the Microbiology Department of the First Affiliated Hospital of Guangxi Medical University)

[0057] Methicillin-resistant Staphylococcus aureus (MRSA) clinical isolate: MRSA 17546 (t037) (identified and provided by the Microbiology Department of the First Affiliated Hospital of Guangxi Medical University).

[0058] 3. Main reagents and drugs

[0059] LB agar, LB broth (Sigma company); absolute ethanol, 75% ethanol, sodium chloride (domestic analytical grade); chloral hydrate (domestic analytical grade); glutaraldehyde (Sigma company), baicalein (Sigma company ), linezolid (Sigma Company), formalin (domestic analytical grade), dimethyl sulfoxide (D...

Embodiment 2

[0110] Embodiment 2 pharmaceutical composition test result

[0111] 1. Gross view of the tissue around the air sac bag of SD rats infected with MRSA-BF:

[0112] Visual view: as Figure 1 to Figure 4 As shown (48 hours after MRSA-BF infection), after the establishment of the infection model, as the infection time prolongs, the inflammatory exudate of the bladder wall of the blank control group gradually increases, but the exudate of each intervention group is less than that of the blank control group, Especially in the baicalein combined with linezolid intervention group, there was almost no exudation of the capsule wall.

[0113] 2. The synergistic effect of baicalein combined with linezolid on the count of viable bacteria in BF on the surface of MRSA-BF infection carrier in SD rats:

[0114]The number of live bacteria in BF on the surface of the carrier in the blank control group, linezolid group, baicalein group and baicalein combined with linezolid rats, CFU (lg10) after...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a composition for inhibiting methicillin-resistant staphylococcus aureus biofilm, belongs to the technical field of microorganism. The composition is prepared from baicalein and an antibacterial medicine, wherein the antibacterial medicine is linezolid. Due to the synergistic effect of the composition provided by the invention, not only is the antibacterial effect of the medicine against methicillin-resistant staphylococcus aureus improved, but the dosage of the antibacterial medicine is also reduced, and the toxic and side effects are further reduced. The composition is a more ideal pharmaceutical composition for interfering with methicillin-resistant staphylococcus aureus biofilm associated infection.

Description

technical field [0001] The invention belongs to the technical field of microorganisms, and in particular relates to a composition for inhibiting methicillin-resistant Staphylococcus aureus biofilm and an application thereof. Background technique [0002] Staphylococcus aureus is a common pathogen causing healthcare-associated and community-acquired infections. More than 50% of hospital-acquired infections caused by Staphylococcus aureus are MRSA. In addition to causing sepsis, endocarditis, suppurative osteomyelitis, and purulent infection of skin tissues in the form of direct infection, MRSA can also colonize and form biofilms on the surface of implantable medical biomaterials, leading to medical The occurrence of material-related infections. Unlike planktonic bacteria, the bacteria in the biofilm state are wrapped by the viscous outer matrix secreted by themselves, making it difficult for conventional doses of antibiotics to kill them, and at the same time they can escap...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K31/5377A61P31/04
CPCA61K31/352A61K31/5377A61K2300/00
Inventor 刘唐娟罗劲陈一强孔晋亮
Owner GUANGXI MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com